BIIB
Price
$131.95
Change
+$3.95 (+3.09%)
Updated
Aug 1 closing price
Capitalization
31.34B
81 days until earnings call
ILMN
Price
$94.66
Change
-$8.05 (-7.84%)
Updated
Aug 1 closing price
Capitalization
21.09B
89 days until earnings call
Interact to see
Advertisement

BIIB vs ILMN

Header iconBIIB vs ILMN Comparison
Open Charts BIIB vs ILMNBanner chart's image
Biogen
Price$131.95
Change+$3.95 (+3.09%)
Volume$2.8M
Capitalization31.34B
Illumina
Price$94.66
Change-$8.05 (-7.84%)
Volume$4.77M
Capitalization21.09B
BIIB vs ILMN Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), DaVita (NYSE:DVA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The diseases theme includes pharmaceutical, biotech, and medical facilities companies that work toward the cure and treatment of diseases. For instance, DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. Gilead Sciences discovers, develops, and commercializes medicines for the treatment of human immunodeficiency virus (HIV) as well as other drugs that treat liver diseases. Still another company in the group is NeoGenomics, a company that operates a network of cancer-focused genetic testing laboratories. The group is part of the overall healthcare sector with a specific focus on treating or curing diseases. This area tends not to depend on the overall economy for its growth as healthcare is less cyclical than other sectors.

Market Cap

The average market capitalization across the diseases Theme is 31.51B. The market cap for tickers in the group ranges from 44.57K to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is ARDS at 44.57K.

High and low price notable news

The average weekly price growth across all stocks in the diseases Theme was 2%. For the same Theme, the average monthly price growth was 10%, and the average quarterly price growth was -7%. DRRX experienced the highest price growth at 223%, while CANF experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the diseases Theme was 22%. For the same stocks of the Theme, the average monthly volume growth was 40% and the average quarterly volume growth was 113%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 80
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 84
Seasonality Score: -19 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN).

Market Cap

The average market capitalization across the group is 26.22B. The market cap for tickers in the group ranges from 21.09B to 31.34B. BIIB holds the highest valuation in this group at 31.34B. The lowest valued company is ILMN at 21.09B.

High and low price notable news

The average weekly price growth across all stocks in the group was -7%. For the same group, the average monthly price growth was -3%, and the average quarterly price growth was -19%. BIIB experienced the highest price growth at 0%, while ILMN experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the group was 108%. For the same stocks of the group, the average monthly volume growth was 43% and the average quarterly volume growth was 149%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 82
P/E Growth Rating: 93
Price Growth Rating: 54
SMR Rating: 82
Profit Risk Rating: 100
Seasonality Score: -32 (-100 ... +100)
VS
BIIB vs. ILMN commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and ILMN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (BIIB: $131.95 vs. ILMN: $94.66)
Brand notoriety: BIIB and ILMN are both notable
BIIB represents the Pharmaceuticals: Major, while ILMN is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIIB: 195% vs. ILMN: 216%
Market capitalization -- BIIB: $31.34B vs. ILMN: $21.09B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. ILMN’s [@Medical Specialties] market capitalization is $21.09B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileILMN’s FA Score has 0 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • ILMN’s FA Score: 0 green, 5 red.
According to our system of comparison, ILMN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 2 TA indicator(s) are bullish while ILMN’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 2 bullish, 6 bearish.
  • ILMN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ILMN is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +0.33% price change this week, while ILMN (@Medical Specialties) price change was -13.39% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.03%. For the same industry, the average monthly price growth was +6.32%, and the average quarterly price growth was +13.91%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.56%. For the same industry, the average monthly price growth was -2.26%, and the average quarterly price growth was -4.37%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

ILMN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.03% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Medical Specialties (-2.56% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($31.3B) has a higher market cap than ILMN($21.1B). ILMN has higher P/E ratio than BIIB: ILMN (49.50) vs BIIB (26.95). BIIB YTD gains are higher at: -13.713 vs. ILMN (-29.163). BIIB has higher annual earnings (EBITDA): 2.04B vs. ILMN (-608M). ILMN (1.05B) and BIIB (1.05B) have equal amount of cash in the bank . ILMN has less debt than BIIB: ILMN (2.26B) vs BIIB (7.34B). BIIB has higher revenues than ILMN: BIIB (9.84B) vs ILMN (4.5B).
BIIBILMNBIIB / ILMN
Capitalization31.3B21.1B148%
EBITDA2.04B-608M-335%
Gain YTD-13.713-29.16347%
P/E Ratio26.9549.5054%
Revenue9.84B4.5B218%
Total Cash1.05B1.05B100%
Total Debt7.34B2.26B324%
FUNDAMENTALS RATINGS
BIIB vs ILMN: Fundamental Ratings
BIIB
ILMN
OUTLOOK RATING
1..100
7067
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7194
PRICE GROWTH RATING
1..100
6246
P/E GROWTH RATING
1..100
9592
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ILMN's Valuation (78) in the Biotechnology industry is in the same range as BIIB (87). This means that ILMN’s stock grew similarly to BIIB’s over the last 12 months.

ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that ILMN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as ILMN (94). This means that BIIB’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's Price Growth Rating (46) in the Biotechnology industry is in the same range as BIIB (62). This means that ILMN’s stock grew similarly to BIIB’s over the last 12 months.

ILMN's P/E Growth Rating (92) in the Biotechnology industry is in the same range as BIIB (95). This means that ILMN’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBILMN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
53%
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VGI7.880.01
+0.13%
VIRTUS GLOBAL MULTI-SECTOR Income FUND
ARLU28.34N/A
N/A
AllianzIM U.S. Equity Buffer15 UncAprETF
FIRI18.94N/A
N/A
FIRE Funds Income Target ETF
DJAN40.58-0.34
-0.82%
FT Vest US Equity Dp Bffr ETF Jan
TILT224.75-3.71
-1.62%
FlexShares Mstar US Mkt Factors Tilt ETF

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+3.09%
PFE - BIIB
53%
Loosely correlated
+0.86%
MRK - BIIB
47%
Loosely correlated
-3.01%
SNY - BIIB
46%
Loosely correlated
+2.43%
NVS - BIIB
46%
Loosely correlated
+1.37%
AMGN - BIIB
46%
Loosely correlated
-1.49%
More

ILMN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with A. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ILMN
1D Price
Change %
ILMN100%
-7.84%
A - ILMN
65%
Loosely correlated
-1.14%
BIO - ILMN
64%
Loosely correlated
+17.63%
BRKR - ILMN
64%
Loosely correlated
-1.14%
RVTY - ILMN
63%
Loosely correlated
-2.88%
IQV - ILMN
61%
Loosely correlated
-1.83%
More